Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (adalimumab) was the only FDA-approved therapy for HS until October 2023, when the FDA approved Cosentyx for moderate to severe HS, the same patient population for whom Humira is specifically approved. Notably, depending on their specific symptoms, patients may initially receive off-label treatment with other agents, such as antibiotics and immunosuppressants, before their physician prescribes an approved biologics. Alternative targeted therapies (e.g., Johnson & Johnson Innovative Medicine’s Remicade [infliximab]) may be used off-label for more-severe disease and for patients who do not respond to Humira or Cosentyx. This offers manufacturers and developers of HS therapies insights into treatment patterns and market trends.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HS patients?
- How have Humira and Cosentyxbeen integrated into the treatment algorithm, and what is its source of business?
- What percentage of HS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithim.
Geography: United States
Real-world data: U.S. pharmacy and medical claims data
Key drugs: Humira, infliximab biosimilars, Enbrel, Stelara, Simponi, clindamycin, doxycycline, acitretin, methotrexate, dapsone, cyclosporine, tacrolimus, Otezla, Cosentyx, Taltz, Tremfya, Skyrizi, Ilumya, Cimzi
Key analyses: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
